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Background: Palliative surgery followed by postoperative chemotherapy is a challenging approach in the
treatment of stage IV gastric cancer yet patients must be carefully selected on the basis of likely clinical benefit.
Methods: The records of 218 patients with histological diagnosis of gastric adenocarcinoma who underwent
palliative surgery followed by postoperative chemotherapy were retrospectively reviewed. Twelve potential
prognostic variables including tumour DNA index and serum IgG anti- Helicobacter pylori (HP) antibodies were
evaluated for their influence on overall survival by multivariate analysis.
Results: The median survival was 13.25 months [95% Confidence Interval (CI) 12.00, 14.50]. Three factors were
found to have an independent effect on survival: performance status (PS) [PS 60–70 vs. 90–100 Hazard Ratio (HR)
1.676; CI 1.171-2.398, p = 0.005], liver metastases (HR 1.745; CI 1.318-2.310, p< 0.001), and DNA Index as assessed by
Image cytometry (2.2-3.6 vs. >3.6 HR 3.059; CI 2.185-4.283, p< 0.001 and <2.2 vs. >3.6 HR; 4.207 CI 2.751-6.433
<0.001). HP infection had no statistically significant effect on survival by either univariate or multivariate analysis.
Conclusion: Poor pre-treatment PS, the presence of liver metastasis and high DNA Index were identified factors
associated with adverse survival outcome in patients with Stage IV gastric cancer treated with palliative
gastrectomy and postoperative chemotherapy. HP infection had no influence on survival of these patients.Background
Gastric adenocarcinoma is an aggressive tumour account-
ing for the second leading cause of cancer specific mortal-
ity worldwide. Surgical resection remains the main
curative treatment for gastric cancer although it remains
applicable in only 10–20% of cases who present with lim-
ited stage disease [1].
The role of palliative gastrectomy in stage IV gastric
cancer [defined as M1 and any T or N according to the
American Joint Commission of Cancer (AJCC, 7th edi-
tion) criteria] is still controversial. A randomized con-
trolled trial has started in both Japan and Korea aiming
to evaluate the role of gastrectomy in the management
of advanced gastric cancer and results are awaited [2];* Correspondence: ssougiou@med.uoa.gr
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reproduction in any medium, provided the ornevertheless, a number of studies, including one from
our group, have shown a survival benefit [3-6].
Furthermore, systemic chemotherapy for advanced
gastric adenocarcinoma has proven of limited value
due to the low response rates and severe adverse
effects [4-8]. However, as both palliative surgery and
postoperative chemotherapy have evolved as independ-
ent prognostic factors for survival previously [6-8], it
would be important to identify factors which could
predict survival benefit in patients selected for a com-
bined treatment with palliative gastrectomy followed
by systemic chemotherapy.
In this study we explored the above notion by per-
forming an analysis of prognostic factors in a subgroup
of patients from our previously described cohort who
received palliative surgery followed by postoperative
chemotherapy. The pool of prognostic factors investi-
gated was expanded with the addition of tumour DNA
content (DNA Index) and H. Pylori (HP) infection.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient Characteristics
Descriptive Statistics Count %
Age ≤60 101 46.3%
>60 117 53.7%
Gender Male 147 67.4%
Female 71 32.6%
60-70 66 30.3%
Karnofsky PS 80 84 38.5%
90-100 68 31.2%
1 11 5.0%
Histological Grade 2 129 59.2%
3 78 35.8%
Lymph Node Metastasis No 45 20.6%
Yes 173 79.4%
Liver Metastasis No 112 51.4%
Yes 106 48.6%
Lung Metastasis No 201 92.2%
Yes 17 7.8%
Ovary Metastasis No 197 90.4%
Yes 21 9.6%
Bone Metastasis No 211 96.8%
Yes 7 3.2%
Peritoneal dissemination No 122 56.0%
Yes 96 44.0%
Albumin (normal range >3.4 g/dl) Normal 137 62.8%
Low 81 37.2%
CRP (normal range ≤5 mg/dl) Normal 132 60.6%
High 86 39.4%
HP No 142 65.1%
Yes 76 34.9%
CEA ≤5 112 51.4%
>5 106 48.6%
CA19-9 ≤30 86 39.4%
>30 132 60.6%
CA 72-4 ≤7 40 18.3%
>7 178 81.7%
<2.2 88 40.4%
DNA Index 2.2-3.6 88 40.4%
>3.6 42 19.2%
PS Performance Status, CRP C-Reactive Protein, HP Helicobacter Pylori, CEA
Carcinoembryonic Antigen CA 19–9 Cancer Antigen 19–9, CA 72–4 Cancer
Antigen 72–4.
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Patients and data sources
The patient cohort has been described in detail else-
where [6]. Briefly, this included 311 consecutive patients
with a histological diagnosis of gastric adenocarcinoma
(noncardia) from a single Oncology Center, treated out-
side of clinical trials. In this subgroup analysis data from
218/311 patients who underwent palliative surgery followed
by chemotherapy [Leucovorin modulated 5-Fluorouracil
(5-FU), or combination chemotherapy regimens including
combination treatments based on Epirubicin, Oxaliplatin
and Capecitabine according to evolving protocols] were
retrospectively reviewed for prognostic factors affecting
overall survival (OS). OS was calculated from time of
diagnosis to death due to gastric cancer-related compli-
cations. Records with complete data (for the parameters
used as prognostic factors) were included in the analysis.
The study was approved by the Ethical Committee for
Research Projects of Laiko Hospital, Athens, Greece.
Prognostic variables
Twelve putative clinicopathological prognostic variables
were selected for this analysis (Table 1). Patient-related
factors included age (≤60 years or >60 years), gender,
and pre-treatment performance status (PS) according to
the Karnofsky Performance Status Scale Index. Tumor-
related factors included histological grading according
the World Health Organisation (WHO) system, location
of metastases: local invasion, lymph nodes, liver, lung,
ovaries, bone, abdomen/peritoneum; and biochemical/
serological parameters. For the latter, group categoriza-
tions were used: for carcinoembryonic antigen (CEA):
normal ≤ 5 ng/dl vs. elevated >5 ng/dL; for cancer anti-
gen 19-9 (CA 19-9): values ≤ 30 U vs. >30 U; for cancer
antigen 72–4 (CA 72–4): normal ≤ 7 U/ml vs. elevated
>7U/ml; for C-reactive protein (CRP): normal ≤5 mg/dl
vs. elevated >5 mg/dl; for Albumin normal >3.4 g/dL
vs. decreased ≤3.4 g/dL and for HP infection infected vs.
not infected; for DNA Index, group categorization was
also applied for analytical purposes: <2.2 (Low), 2.2-3.6
(Intermediate), >3.6 (High).
DNA image cytometry (DNA Index)
For DNA measurements the Feulgen staining technique
was applied which labels DNA as magenta and the inten-
sity of the stain is directly proportional to the amount of
DNA present. Briefly, formalin-fixed paraffin-embedded
tissue sections (6 μm) were de-paraffinized with xylene
for 30 min, rehydrated with graded alcohol, and then
immersed in 0.1 M hydrochloric acid at 60°C for 5 min.
Slides were then immersed in Schiff reagent for 30 min
until the nuclei were stained, and then transferred dir-
ectly to bisulfate water, followed by rinsing under run-
ning tap water. Following dehydration, the samples weretreated with xylene, mounted in DPX and stored in shade.
Nuclear morphometry was performed using a Nikon
eclipse microscope (Nikon, Japan) connected with a Nikon
CCD videocamera and an IBM Pentium 4/ PC with the
appropriate Cell Measurement Software (Image Pro Plus
Figure 1 Overall Survival.
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described previously by our group [9].
This analysis configuration permits operator-dependent
selection and measurement of DNA content using a mag-
nification of x200. Areas of the Feulgen-stained sections
containing pathological lesions as defined by adjacent
H&E stained slides were selected for DNA content ana-
lysis. A total of 200–300 nuclei with clear boundaries
appearing to have no loss of membrane integrity were
identified for analysis from each tissue sample, overlap-
ping nuclei were excluded. By the calculation of configur-
ation the software discharges the majority of overlapping
nuclei, internal reference cells are selected and additional
non-diagnostic nuclei are discarded by supplementary ob-
ligatory visual review. Reference cells’ coefficient of vari-
ation is limited to 5%, automatically. Gray levels in the
microscopic image were transformed into digitalized sig-
nals and evaluated, with the image analysis system allowing
differentiation between gray level intervals. Cytometrical
measurements were calculated automatically according to
the algorithms described previously by measuring the nu-
clear integrated optical density (IOD), which represents the
cytometrical equivalent of its DNA content [10].
The procedure was performed for all nuclei and the
overall mean represented DNA content or DNA index
(DI). The mean IOD of control cells (human lympho-
cytes) served as the diploid standard (2c) and reference
for DI calculation for targeted cells. Subsequently DNA
histograms were generated. A tumour was classified as
diploid if the DI ranged from 0.9 to 1.1 and the relevant
DNA histogram revealed only 1 peak at 2c and aneu-
ploid if any from the previous 2 criteria was absent.
Η. Pylori serology
Sera from all patients were analysed for HP with an
enzyme-linked immunosorbent assay (ELISA) IgG sero-
logic test for (Allergy Immunotechnologies Inc., Newport
Beach, CA, USA) in accordance to the manufacturer’s
instructions. HP antibody titers higher than 155 mU/L
were considered positive and lower than 155 mU/L
negative. The specificity and sensitivity of the serology
test has been estimated to be 95% and 90% [11].
Statistical analysis
The primary end point of the study was Overall Survival
(OS). A prognostic model was established by searching
all variables that were significantly related to OS at a
level of P values≤ 0.05 in the univariate analysis. De-
scriptive Statistics were used to calculate frequencies
and percentages for all variables involved. The Kaplan-
Meier method was used to estimate the effect of the dif-
ferent variables on OS. Survival rates among categories
(existence of factors or not) were compared for statis-
tical differences using the Log-rank analysis. Multivariateanalysis was subsequently carried out using stepwise
Cox proportional hazards modelling for OS; best model
was constructed using automated methods. Hazard ratio
(HR) values together with the 95% Confidence interval
(CI) are presented for all variables studied. All categor-
ical variables were compared using a baseline category
as reference. All analyses were conducted at a 5% signifi-
cant level using SPSS v12.0 statistical package.
Results
Patients
218 cases of gastric cancer patients that have undergone
surgery followed by chemotherapy were included in this
analysis. The median age was 61 (Mean ± Standard De-
viation (SD): 59 ± 9.53) years. Patient characteristics are
presented in Table 1.
Survival analysis
No patient was alive by the time of this analysis. OS was
calculated for all patients in weeks. The 1-year Overall
Survival was 51.38%. The median survival time for all
patients was 13.25 months [95% Confidence Interval
(CI) 12.00, 14.50] and the mean was 16.00 months [95%
confidence Interval (CI) 14.50, 17.50] (Figure 1).
Univariate analysis
At univariate analysis, using log rank tests seven of the
parameters studied were found to adversely relate to sur-
vival (Table 2): PS (p< 0.001), presence of liver metastasis
(p< 0.001), albumin≤ 3.4 g/dL (P=0.002), CRP >5 mg/dL
Table 2 Univariate Analysis of Survival
UNIVARIATE ANALYSIS OF SURVIVAL
Variable MST 1-year survival % P-value
Age Category ≤ 60 16.50 53.00% 0.591
>60 15.75 47.86%
Gender Male 15.75 50.34% 0.515
Female 16.50 49.3%
60-70 11.75 30.30%
Karnofsky PS 80 16.75 52.40% <0.001
90-100 19.25 63.20%
1 14.50 36.40% 0.092
Histological Grade 2 17.25 54.30%
3 14.25 44.87%
Lymph node metastasis No 13.50 28.89% 0.051
Yes 16.75 56.65%
Liver metastasis No 19.25 63.39% <0.001
Yes 12.75 37.74%
Lung metastasis No 16.25 52.24% 0.185
Yes 12.75 35.29%
Ovarian metastasis No 16.00 51.27% 0.579
Yes 17.00 47.62%
Bone metastasis No 16.25 51.18% 0.282
Yes 12.25 42.86%
Peritoneal dissemination No 16.75 54.90% 0.319
Yes 15.00 43.70%
Albumin Normal 18.00 57.66% 0.002
Low 12.75 38.30%
CRP Normal 18.00 56.06% <0.001
High 12.75 43.02%
HP No 15.50 48.59% 0.35
Yes 17.25 52.63%
CEA ≤ 5 15.00 45.54% 0.143
> 5 17.00 52.83%
CA 19-9 ≤ 30 18.25 58.14% 0.019
> 30 14.50 46.21%
CA 72-4 ≤ 7 21.75 65.00% 0.002
> 7 14.75 47.46%
Low 22.50 73.86%
DNA Index Medium 12.75 35.20% <0.001
High 09.50 23.81%
MST Median Survival Time, PS Performance Status, CRP C-Reactive Protein, HP
Helicobacter Pylori, CEA Carcinoembryonic Antigen, CA 19–9 Cancer Antigen
19–9, CA 72–4 Cancer Antigen 72–4.





PS (60–70 vs. 90–100) 0.005 1.676 1.171 2.398
PS (80 vs. 90–100) 0.161 1.263 0.911 1.753
Liver Metastasis (Yes vs. No) <0.001 1.745 1.318 2.310
DNA Index (2.2-3.6 vs. <2.2) <0.001 3.059 2.185 4.282
DNA Index (>3.6 vs. <2.2) <0.001 4.207 2.751 6.433
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(p=0.002) and DNA Index (p< 0.001). H. Pylori infection
was not found to be significantly associated with OS
(p=0.35).Multivariate analysis
Results of the multivariate analysis are presented in Table 3.
Prognostic factors adversely affecting survival were PS, liver
metastasis, and DNA Index. Based on the model, patients
with PS 60–70 had 1.7 times higher possibility of death as
compared to those with a PS 90–100 (HR 1.676; CI 1.171-
2.398, p=0.005), (Figure 2). The presence of liver metas-
tasis was associated with 1.7 times higher possibility of
death (HR 1.745; CI 1.318-2.310, p< 0.001), (Figure 3).
Also, patients with DNA Index >3.6 have 4.2 times
higher chance of death when compared to those with
<2.2 (HR 4.207; CI 2.751-6.433 <0.001), (Figure 4) and
patients with DNA Index 2.2-3.6 had a 3.05 higher
probability of death when compared to those with <2.2
(HR 3.059; CI 2.185-4.283, p< 0.001), (Figure 4).
Discussion
Following the publication of the Intergroup-0116
(INT-0116) and the MAGIC studies [12,13] which
demonstrated a survival benefit from the combination
of either postoperative chemoradiation or perioperative
chemotherapy with surgery for resectable oesophago-
gastric cancer, a number of studies have suggested that
the survival advantage conferred by this multimodality
approach could be cautiously extended to patients with
Stage IV disease. However, as this approach is poten-
tially associated with high incidence of side effects it
would be important to identify factors that predict sur-
vival to assist with patient selection and justify indica-
tion and feasibility.
Our retrospective analysis has evolved PS, liver metas-
tasis and DNA content (DNA Index) as independent pre-
dictors of survival in our patient cohort which included
patients with Stage IV gastric adenocarcinoma treated
with palliative gastrectomy and systemic chemotherapy.
HP infection was not identified as significant prognostic
indicator by either univariate or multivariate analysis.
Although numerous studies report the detrimental ef-
fect of poor PS on survival in Stage IV gastric cancer,
these mostly involve patients treated with palliative
chemotherapy alone [14-16] like the one by Kim et al.
which involved 304 consecutive patients with newly
diagnosed metastatic or recurrent gastric cancer treated
with one or more cycles of cisplatin-based chemotherapy
Figure 2 Overall Survival according to Performance Status.
Figure 3 Overall Survival according to Liver metastasis.
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prognostic significance of PS in a multimodality setting
which involved intraperitoneal chemotherapy to treat
intra-abdominal gross residual lesions after palliative
gastrectomy with maximal cytoreduction. This particular
study by Jeung et al. which involved 53 patients identified
PS as the only significant defining factor for progression-
free survival (P = 0.009) by multivariate analysis [17].
Liver metastasis is also a well-established prognostic in-
dicator in patients with advanced gastric cancer treated
with either palliative chemotherapy or surgery but not the
combination. For example a pool analysis of 1080 chemo-
therapy naïve patients with locally advanced or metastatic
oesophagogastric cancer by Chau et al. identified liver
metastasis as an adverse prognostic factor by multivari-
ate analysis [14]. Similarly, liver invasion has evolved as
an independent survival indicator in a large prospective
study involving 539 patients with advanced gastric can-
cer that had undergone surgical resection [18].
The prognostic value of DNA content in gastric cancer
as measured by the DNA Index (DNA ploidy) is contro-
versial as divergent DNA content analysis results have
been reported by various studies. These are thought to
reflect objective differences in the analytical techniques
employed (image cytometry vs. flow cytometry) and
intratumoural DNA ploidy heterogeneity. Image cyto-
metry is considered superior to flow cytometry as it
allows direct visualization and selection of tumour cells
for inclusion in the DNA measurement. This qualitativefeature appears to outbalance its lower throughput
when compared with flow cytometry as was illustrated
in a recent study by Belien et al. on the prognostic value
of both image and flow cytometric analysis of DNA con-
tent in gastric cancer [19]. Their patient cohort con-
sisted of 221 cases of gastric cancer analyzed for DNA
content using the guidelines of the European consensus
report on standardization of diagnostic DNA image
cytometry and flow cytometry [20,21]. Although this
study has demonstrated equal sensitivity for both meth-
ods in detecting DNA non-diploid gastric cancers,
image cytometry DNA content analysis outperformed
flow cytometry in predicting survival by multivariate
analysis.
Other studies demonstrating the adverse prognostic
significance of DNA analysis in advanced gastric cancer
includes a study by Kimura et al. who analyzed the
DNA content of 270 patients with advanced gastric can-
cer by flow cytometry to conclude that high DNA ploidy
index was the third strongest prognostic factor for sur-
vival behind peritoneal dissemination and liver metasta-
ses (P< 0.01) [22]. A different study by Baba et al.
including 93 patients with advanced gastric cancer
showed that high DNA ploidy manifests with higher
Figure 4 Overall Survival according to DNA Index.
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invasion conferring a poor 5- year survival in elderly
patients (P< 0.05) [23]. Similarly the flow cytometric
analysis of gastric carcinomas performed by Danova
et al. to evaluate ploidy patterns and the distribution of
cells in the different cell cycle phases has demonstrated
that DNA aneuploidy was a strong independent adverse
prognostic factor for survival in patients with limited or
advanced stage gastric cancer [24].
The relative consistency of reports on DNA Index ana-
lysis measurements in the few studies publishing results
on advanced gastric cancer, irrespectively of the method
applied, strengthens the validity of our data. This may be
explained by the observation that aneuploidy appears to
be more frequent in advanced gastric cancer and the
majority of these aneuploid tumors are not DNA ploidy
heterogeneous. That was depicted in a study by Oster-
held et al. who performed DNA cytophotometry on
multiple samples collected from 16 advanced gastric car-
cinomas and found 15 DNA-aneuploid tumours (94%)
and one diploid tumour; multiple DNA-stemlines were
found in 4 cases (26%). Furthermore, analysis of prolifera-
tive activity performed on the same samples revealed
higher proliferation rate in DNA aneuploid homogeneous
tumours than in aneuploid heterogeneous tumours and
heterogeneous tumours did not overexpress p53. The
authors suggested that the higher proliferative activity in
homogeneous-aneuploid carcinomas and their morefrequent overexpression of p53 support the hypothesis
that in gastric cancer tumour progression implies the de-
velopment of a dominant and more aggressive (higher
proliferative activity, p53 overexpression) aneuploid cell
clone [25]. This is particularly important as it has been
shown that it is the DNA index of the subpopulation that
is most widely distributed within gastric tumour is signifi-
cantly associated with lymph node metastases (P< 0.001)
and histologic grade (P< 0.001) [26].
Based on our analysis, the high DNA content (DNA
Index) along with the poor PS and the presence of liver
metastasis have evolved as independent predictors of
survival in patients with Stage IV gastric adenocarcin-
oma treated with palliative gastrectomy and systemic
chemotherapy. Since all these three variables can be
assessed in preoperative biopsies, they may serve as a
prognostic tool in order to preoperatively select patients
eligible for palliative gastrectomy; however, prospective
studies are needed to confirm this hypothesis.
There is considerable evidence to support causality be-
tween HP and sporadic noncardia gastric cancer [22].
For example, an individual-subject meta-analysis of 12
prospective serological studies including 1228 gastric can-
cer cases, in whom HP status was assessed by anti HP IgG
antibodies with ELISA, reported that the relative risk of
non cardia gastric cancer associated with HP infection is
5.9 [27]. It is generally accepted that HP infection leads to
gastric cancer by inducing sequential alterations of the
gastric mucosa, including chronic inflammation, atrophy
and intestinal metaplasia, the latter considered as precan-
cerous lesions. The extension of the preneoplastic lesions
in the gastric mucosa although increases the risk for can-
cer development, creates an unfavorable environment for
HP colonization and may account for the under-detection
of HP infection in blood collected after the diagnosis of
gastric cancer in case controlled studies [28]. In addition,
it has been shown that conventional ELISAs used to assess
serological presence of HP IgG antibodies in most epi-
demiological studies are likely to produce false-negative
results for gastric cancer patients, as compared to popula-
tion controls, which may further underestimate the risk
[29,30]. In view of the above considerations, results from
studies investigating the association of HP infection and
prognosis in gastric cancer should be viewed with caution.
Meimarakis et al. used bacterial culture, histological
analysis and serology (HP IgA and IgG ELISA) to assess
HP status in 166 patients with gastric cancer and reported
HP infection to be an independent prognostic factor for
relapse free survival (HR 2.16, 95% CI 1.33-3.49) and OS
(HR 2.00, 95%CI 1.22-3.57). Yet their patient cohort was
different from ours as all their patients underwent curative
resection (i.e. R0) followed by adjuvant treatment in 12
cases only (10 patients received intraoperative radiother-
apy and 2 had postoperative chemotherapy with Cisplatin
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Equivalent results were reported by Marrelli et al in a
cohort of 297 patients with similar characteristics [32].
Furthermore, HP negative status (as assessed by hist-
ology) was reported to be the most significant inde-
pendent prognostic factor of poor OS (HR 3.45, 95% CI:
2.43-4.89, p< 0.0001) in a different study which included
only patients with locally advanced gastric cancer who
underwent adjuvant chemotherapy after curative resection
(≥D2 dissection) [33]. An attempt to explain the associ-
ation between HP negativity and adverse survival implies
a likely contribution of HP infection in augmenting anti-
tumour immunity, especially in early stage gastric cancer
[31], but this needs further validation.
However, in our study which included patients with
advanced gastric cancer no association between HP in-
fection status and survival was observed. HP seropreva-
lance was observed in only 34.9% of our patients as
compared to approximately 65% expected for this age
group (55–64 years) in Greece [34]. This may be related
to the inferior methodology (ELISA) applied to assess
HP positivity or it may simply depict mucosal changes
and progressive pH alkalization in advanced gastric can-
cer that create a less favorable environment for HP
colonization, as we mentioned above and has also been
suggested by others [35]. Moreover, our findings are in
agreement with a recent report by Qiu et al who used
real-time PCR for HP detection in 157 gastric cancer
patients and found no significant association between
HP infection and OS or relapse-free survival in patients
who underwent curative surgery [36].
The limitations of our study evolve around its retro-
spective nature and the objectivity of the methodologies
used to assess key indicators such as HP status and
DNA Index. Despite these limitations it has clinical rele-
vance as we have validated a number of factors that
could potentially be used to assess the likelihood of clin-
ical benefit of a multimodal therapeutic approach with
the combination of palliative gastrectomy and post-
operative chemotherapy in gastric cancer patients with
stage IV disease.
Conclusion
In the present study a number of factors which could be
used to predict survival in gastric cancer patients with
Stage IV disease treated with palliative gastrectomy and
postoperative chemotherapy have been identified. Poor
pre-treatment PS, the presence of liver metastasis and
high DNA Index were shown to be associated with ad-
verse prognosis; the effect of HP infection status on sur-
vival has yet to be defined.
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